Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Retrieved on:
Monday, March 25, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Interest, Dizziness, Attack, Disease, PD, Webcast, Patient, HAE, Allergy, Quality of life, IND, Injection site reaction, Rash, Plasma kallikrein, Investment, Therapy, Hereditary angioedema, Safety, Charité, Pharmacokinetics, Pain, Multimedia, Pharmaceutical industry
Based on the positive results, Astria plans to advance STAR-0215 to Phase 3 development with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026.
Key Points:
- Based on the positive results, Astria plans to advance STAR-0215 to Phase 3 development with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026.
- Initial safety and efficacy data from Q3M and Q6M dosing in the ALPHA-SOLAR trial are expected mid-2025.
- Pending regulatory feedback, the Company expects to start a pivotal Q3M Phase 3 trial in Q1 2025, with top-line results expected by year-end 2026.
- Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com or with following the link https://lifescievents.com/event/astriatx/ .